Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jupiter Neurosciences, Inc. ( (JUNS) ) has provided an announcement.
On May 19, 2026, Jupiter Neurosciences entered into a non-binding term sheet with PharmAla Biotech to license exclusive, perpetual U.S. rights to ALA-002, a patented, non-racemic MDMA formulation recognized by the FDA as a Novel Chemical Entity. The deal would transfer related intellectual property, regulatory materials, inventory, and key agreements, potentially expanding Jupiter’s CNS pipeline into next-generation psychedelic therapeutics.
Under the proposed terms, PharmAla would receive $3.33 million upfront in a mix of cash and Jupiter equity, with additional development and commercialization milestones and a low single-digit royalty on U.S. sales, while Jupiter has deposited $600,000 in escrow that converts to a reverse termination fee if no definitive agreement is signed within 90 days. The transaction, announced on May 20, 2026, is subject to due diligence, regulatory and shareholder approvals, and reflects Jupiter’s bid to capitalize on a projected multi-billion-dollar U.S. psychedelic medicine market reshaped by an April 18, 2026 executive order accelerating access to investigational psychedelic therapies.
The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.
More about Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, with a pipeline that includes JOTROL, a proprietary resveratrol formulation now in a Phase IIa Parkinson’s trial. The company also markets Nugevia, a consumer longevity supplement, positioning Jupiter at the intersection of CNS therapeutics and brain health-focused wellness products.
PharmAla Biotech Holdings Inc. is a biotechnology company specializing in the research, development, and manufacturing of MDXX-class molecules, and is currently the only firm supplying clinical-grade MDMA for patient treatments outside clinical trials. Through its Cortexa joint venture in Australia and participation in U.S. VA and DHA-sponsored trials, PharmAla occupies a leading role in the emerging regulated psychedelic therapeutics market.
Average Trading Volume: 122,798
Technical Sentiment Signal: Sell
Current Market Cap: $12.06M
See more insights into JUNS stock on TipRanks’ Stock Analysis page.